Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Lidsky ME, Speicher PJ, Jiang B, Tsutsui M, Tyler DS.

J Surg Oncol. 2014 Mar;109(4):357-65. doi: 10.1002/jso.23502. Epub 2013 Nov 20. Review.

2.

Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.

Rashid OM, Sloot S, Zager JS.

Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1355-64. doi: 10.1517/17425255.2014.951330. Epub 2014 Sep 1. Review.

PMID:
25176398
3.

Isolated limb infusion: technical aspects.

Kroon HM, Huismans A, Waugh RC, Kam PC, Thompson JF.

J Surg Oncol. 2014 Mar;109(4):352-6. doi: 10.1002/jso.23540. Epub 2013 Dec 24. Review.

PMID:
24374797
4.

Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Han D, Beasley GM, Tyler DS, Zager JS.

Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1383-94. doi: 10.1517/17425255.2011.609555. Epub 2011 Oct 7. Review.

5.

In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS.

J Am Coll Surg. 2004 Sep;199(3):419-27.

PMID:
15325612
6.

Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy.

Grünhagen DJ, Kroon HM, Verhoef C.

Am Soc Clin Oncol Educ Book. 2015:e528-34. doi: 10.14694/EdBook_AM.2015.35.e528. Review.

7.

Future directions in regional treatment strategies for melanoma and sarcoma.

Beasley GM, Ross MI, Tyler DS.

Int J Hyperthermia. 2008 May;24(3):301-9. doi: 10.1080/02656730701827573. Review.

PMID:
18393007
8.

Current status of hyperthermic limb perfusion for in-transit melanoma.

Ross MI.

Int J Hyperthermia. 2008 May;24(3):205-17. doi: 10.1080/02656730801944930. Review.

PMID:
18392999
9.

Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?

Hoekstra HJ, Veerman K, van Ginkel RJ.

J Surg Oncol. 2014 Mar;109(4):338-47. doi: 10.1002/jso.23552. Epub 2014 Jan 9. Review.

PMID:
24403098
10.

Commentary on pharmacotherapy of regional melanoma therapy.

Zager JS, Delman KA.

Expert Opin Pharmacother. 2010 Jan;11(1):1-3. doi: 10.1517/14656560903428011.

PMID:
20001424
11.

The role of regional chemotherapy in the management of extremity soft tissue malignancies.

Smith HG, Hayes AJ.

Eur J Surg Oncol. 2016 Jan;42(1):7-17. doi: 10.1016/j.ejso.2015.08.165. Epub 2015 Sep 4. Review.

PMID:
26382102
12.

Predicting disease progression after regional therapy for in-transit melanoma.

Lidsky ME, Turley RS, Beasley GM, Sharma K, Tyler DS.

JAMA Surg. 2013 Jun;148(6):493-8. doi: 10.1001/jamasurg.2013.695.

13.

Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.

Ma Q, Zhao Z, Barber BL, Shilkrut M.

Adv Ther. 2016 Feb;33(2):282-9. doi: 10.1007/s12325-016-0283-z. Epub 2016 Jan 21.

14.

Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.

Kroon HM, Huismans AM, Kam PC, Thompson JF.

J Surg Oncol. 2014 Mar;109(4):348-51. doi: 10.1002/jso.23553. Review.

PMID:
24522939
15.

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.

Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS.

Ann Surg Oncol. 2009 Sep;16(9):2570-8. doi: 10.1245/s10434-009-0563-9. Epub 2009 Jun 19.

PMID:
19543771
16.

Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha.

Deroose JP, Eggermont AM, van Geel AN, Verhoef C.

Curr Opin Oncol. 2011 Mar;23(2):183-8. doi: 10.1097/CCO.0b013e3283424dbc. Review.

PMID:
21150602
17.

Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.

Aloia TA, Grubbs E, Onaitis M, Mosca PJ, Cheng TY, Seigler H, Tyler DS.

Arch Surg. 2005 Nov;140(11):1115-20.

PMID:
16301451
19.

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS.

J Am Coll Surg. 2009 May;208(5):706-15; discussion 715-7. doi: 10.1016/j.jamcollsurg.2008.12.019. Epub 2009 Mar 26.

PMID:
19476821
20.

Isolated limb perfusion: a literature review.

Schaadt J, Crowley R, Miller D, Kavanah M.

J Extra Corpor Technol. 2002 Jun;34(2):130-43. Review.

PMID:
12139123

Supplemental Content

Support Center